Vom Sitzungssaal zum Bohrkern:
750-Millionen-Euro-Finanzier verstärkt Forge – Sichtbares Gold
Anzeige
VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Kürzel: VLA Forum: Aktien Thema: Hauptdiskussion
2,406
EUR
-0,54 % -0,013
20:15:10 Uhr,
Lang & Schwarz
Kommentare 297.101
Registrieren
K
KeineAhnungvonAktien,
01.04.2025 20:04 Uhr
0
gleich rot

Henry1966,
01.04.2025 19:57 Uhr
0
Chikungunya has become an increasingly pressing public health issue, with
outbreaks currently ongoing in India, Brazil and the French Island of La
Réunion. Valneva announced last week that it has responded to the French
government's call for supply of IXCHIQ(®) in La Réunion and that it will provide
40,000 doses to the Island's wholesalers, with an option to provide more(5).
Dr. Richard Hatchett, Chief Executive Officer of the Coalition for Epidemic
Preparedness Innovations (CEPI), commented, 'Cases of chikungunya are increasing
around the world, making populations of all ages vulnerable to the disease's
long-term debilitating effects, such as prolonged joint plan and inflammation.
EC's marketing authorization for use of IXCHIQ(®) in adolescents in the EU is an
important steppingstone that could help accelerate the approval of the vaccine
in this age group in other regions, including areas where the disease is
endemic.'

Henry1966,
01.04.2025 19:57 Uhr
0
IXCHIQ(®) is the world's first licensed chikungunya vaccine available to address
this significant unmet medical need. In addition to its approval in adolescents
and adults in the EU, it is approved in the United States (U.S.)(2), Canada(3)
and the United Kingdom (U.K.)(4) for the prevention of disease caused by the
chikungunya virus in individuals 18 years of age and older. Similar label
extension applications to adolescents were also submitted in the U.S., Canada
and the U.K.
Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, 'Given the
substantial risk that chikungunya presents to individuals residing in or
traveling to endemic regions, it's imperative to ensure the vaccine is available
to all age groups. This adolescent approval marks a crucial milestone toward
introducing a more robust preventative solution against chikungunya in the EU.
Broader accessibility will help provide protection and mitigate the burden of
this debilitating illness, which is continuing to spread in areas that were
previously unaffected.'
B
Boersenhan,
01.04.2025 19:55 Uhr
0
Morgen sehen wir, es war nur ein Aprilscherz

Henry1966,
01.04.2025 19:55 Uhr
0
With this extension, IXCHIQ(®), the first vaccine against the chikungunya virus
(CHIKV), is now available for administration for individuals 12 years of age and
older in the European Union (EU).
Saint Herblain (France), April 1, 2025 - Valneva SE
(https://valneva.com/?lang=fr) (Nasdaq: VALN; Euronext Paris: VLA), a specialty
vaccine company, today announced that the European Commission (EC) has granted
marketing authorization in Europe for Valneva's single-dose vaccine, IXCHIQ(®),
for the prevention of disease caused by the chikungunya virus in individuals 12
years of age and older. This label extension complements the adult marketing
authorization in Europe Valneva received in July 2024(1). With this approval,
IXCHIQ(®) becomes available in the market for adolescents in the EU, Norway,
Liechtenstein and Iceland.

Mölli1972,
01.04.2025 19:40 Uhr
0
Betonung Vergangenheit waren

Ranisch69,
01.04.2025 19:07 Uhr
0
Wahnsinn, waren wie heute 14% im Plus? 😂😼

KaRoLa1960!,
01.04.2025 19:01 Uhr
0
Jetzt noch für die Messdiener in Latein bitte...🙄
s
sometimes,
01.04.2025 18:54 Uhr
0
Gibt es wieder was zum shorten ..das geht Ruck zuck bei den shortfunds. ..

speedbeiryanair,
01.04.2025 18:42 Uhr
0
Astronomisch 🤣
Na wenigstens das Minus von neulich wieder gut gemacht.
Aktienbetrug hat uns sicher nur verarscht und hält noch alle seine Anteile die nun 110% im Plus sind 🤡 🤣

Mimo78,
01.04.2025 18:09 Uhr
0
Die Zielgruppe muss ja enorm sein, wenn der Kurs so anzieht…
R
Regenerator3,
01.04.2025 18:01 Uhr
8
https://valneva.com/press-release/valnevas-chikungunya-vaccine-ixchiq-now-authorized-in-eu-for-adolescents-aged-12-and-above/?lang=de

Henry1966,
01.04.2025 17:56 Uhr
1
LE VACCIN CONTRE LE CHIKUNGUNYA, IXCHIQ®, DÉSORMAIS
AUTORISÉ
CHEZ LES ADOLESCENTS DANS L'UE
Texte original
Pour plus de détails, cliquez sur
(Rédaction de Gdansk)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
k
kaiplan,
01.04.2025 17:53 Uhr
1
🚀🚀🚀🚀
K
KeineAhnungvonAktien,
01.04.2025 17:53 Uhr
0
na endlich kann ich mich impfen lassen
L
Lisboa,
01.04.2025 17:52 Uhr
3
News: Eu-Zulassung ab 12 💪
Mehr zu diesem Wert
|
Thema | ||
---|---|---|---|
1 | VALNEVA SE Hauptdiskussion | ||
2 | Valneva für EK über 15 | ||
3 | Fallneva | ||
4 | Valneva Insolvenz möglich? | ||
5 | Wobsy Valneva | ||
6 | Valneva ohne Politik | ||
7 | Valneva direkt | ||
8 | Valneva Totimpfstoff | ||
9 | Valneva - Tenbagger | ||
10 | Daytrade Valneva |
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Wolfspeed | +14,95 % | |
2 | BTCS | +104,22 % | |
3 | Novo Nordisk nach Split | +0,51 % | |
4 | Metaplanet Inc. | ||
5 | TESLA MOTORS Hauptdiskussion | +2,71 % | |
6 | Hims & Hers Health Registered (A) Hauptdiskussion | +2,80 % | |
7 | DAX Hauptdiskussion | +1,09 % | |
8 | NAKIKI eher Bärisch oder doch weiter Bullisch. | +13,91 % | |
9 | für alle, die es ehrlich meinen beim Traden. | ||
10 | TUI Hauptforum | +1,74 % | |
Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Wolfspeed | +14,61 % | |
2 | BTCS | +102,13 % | |
3 | TESLA MOTORS Hauptdiskussion | +2,66 % | |
4 | Novo Nordisk nach Split | +0,53 % | |
5 | Hims & Hers Health Registered (A) Hauptdiskussion | +2,48 % | |
6 | NAKIKI eher Bärisch oder doch weiter Bullisch. | +13,91 % | |
7 | TUI Hauptforum | +1,74 % | |
8 | NVIDIA Hauptdiskussion | +0,87 % | |
9 | TILRAY INC. CL.2 DL-,0001 Hauptdiskussion | +13,22 % | |
10 | PLUG POWER Hauptdiskussion | +3,89 % | |
Alle Diskussionen |